This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chernoff, D. N.
Right arrow Articles by Kolberg, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chernoff, D. N.
Right arrow Articles by Kolberg, J. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, 11 1997, 2740-2744, Vol 35, No. 11
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay [In Process Citation]

DN Chernoff, RC Miner, BS Hoo, LP Shen, RJ Kelso, D Jekic-McMullen, JP Lalezari, S Chou, WL Drew and JA Kolberg
Chiron Diagnostics, Emeryville, California 94608-2916, USA. david_chernoff@cc.chiron.com

Quantification of cytomegalovirus (CMV) DNA in blood may aid in the identification of patients at highest risk for developing CMV disease, the evaluation of new therapeutics, and the prompt recognition of drug- resistant CMV strains. A branched-DNA (bDNA) assay was developed for the reliable quantification of CMV DNA in peripheral blood leukocytes. The bDNA assay allowed for the highly specific and reproducible quantification of CMV DNA in clinical specimens. Furthermore, the bDNA assay was at least as sensitive as culture techniques and displayed a nearly 3 log10 dynamic range in quantification. Changes in CMV DNA levels measured by the bDNA assay in a human immunodeficiency virus- positive patient undergoing therapy were consistent with CMV culture, antigen, and genotype results and correlated with disease progression and resistance markers. The bDNA assay for the quantification of CMV DNA may provide a useful tool that can be used to aid physicians in monitoring disease progression, evaluating therapeutic regimens, and recognizing viral resistance and drug failure.


This article has been cited by other articles:

  • Baldanti, F., Gerna, G. (2003). Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact. J Antimicrob Chemother 52: 324-330 [Abstract] [Full Text]  
  • Revello, M. G., Gerna, G. (2002). Diagnosis and Management of Human Cytomegalovirus Infection in the Mother, Fetus, and Newborn Infant. Clin. Microbiol. Rev. 15: 680-715 [Abstract] [Full Text]  
  • Player, A. N., Shen, L.-P., Kenny, D., Antao, V. P., Kolberg, J. A. (2001). Single-copy Gene Detection Using Branched DNA (bDNA) In Situ Hybridization. J. Histochem. Cytochem. 49: 603-612 [Abstract] [Full Text]  
  • Sia, I. G., Patel, R. (2000). New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients. Clin. Microbiol. Rev. 13: 83-121 [Abstract] [Full Text]  
  • Long, C. M., Drew, L., Miner, R., Jekic-McMullen, D., Impraim, C., Kao, S.-Y. (1998). Detection of Cytomegalovirus in Plasma and Cerebrospinal Fluid Specimens from Human Immunodeficiency Virus-Infected Patients by the AMPLICOR CMV Test. J. Clin. Microbiol. 36: 2434-2438 [Abstract] [Full Text]  
  • Boeckh, M., Boivin, G. (1998). Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications. Clin. Microbiol. Rev. 11: 533-554 [Abstract] [Full Text]